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SCIENTIFIC OPINION 
Statement on the safety of 'Cetyl Myristoleate Complex' as an ingredient in 
food supplements1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
was asked to update its opinion on the safety of „Cetyl Myristoleate Complex‟ (CMC) as a novel food ingredient 
in the light of a new repeated dose 90-day oral toxicity study in mice. In its previous opinion of 2010, the Panel 
concluded that based on the available data, the safety of CMC as an ingredient in food supplements has not been 
established. This conclusion was based on the considerations that in the absence of appropriate data on 
absorption, distribution, metabolism and excretion, the provided toxicological data were insufficient. Whereas 
the applicant considers that the NOAEL of CMC in this new 90-day study was 1000 mg/kg body weight (bw), 
the highest dose tested, the Panel considers that this study and study report has many shortcomings to be a 
reliable source of information supporting the absence of adverse effects of the parent material CMC. The Panel 
concludes that the safety of 'Cetyl Myristoleate Complex' has not been established. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to update its opinion on the safety of „Cetyl Myristoleate Complex‟ (CMC) with 
an intended daily intake of 3.3 g per person per day as a novel food ingredient in food supplements in 
the light of additional information provided by the applicant on a repeated dose 90-day oral toxicity 
study in mice.  
„Cetyl Myristoleate Complex‟ consists of 50 % cetylated fatty acids, 48 % corn starch and 2 % silicon 
dioxide. The applicant proposed a daily intake of 3.3 g CMC [1.65 g cetylated fatty acids (CFAs)] 
which contains approximately 660 mg of both cetyl myristoleate and cetyl myristate, the two main 
compounds of CMC.  
In its previous opinion of 2010, the Panel concluded that based on the available data, the safety of 
CMC as an ingredient in food supplements has not been established. This conclusion was based on the 
considerations that (i) a provided rat study on the absorption and distribution of 14C-labelled cetylated 
fatty acids (CFA) had limitations in the design and the test substance used with respect to the 
proposed novel food ingredient, that (ii) no information was provided on the extent of intestinal 
hydrolysis of the CFA after oral intake, that (iii) limited information was provided on the distribution 
of absorbed unhydrolysed CFA, and that (iv) no information was provided on the metabolism and 
excretion of such intact CFA. In the absence of appropriate data on absorption, distribution, 
metabolism and excretion (ADME), the provided toxicological data were considered insufficient. No 
subchronic oral toxicity study and no chronic toxicity study conducted with cetyl myristoleate or 
CMC had been provided in the original dossier. 
The new 90-day study in mice was claimed by the applicant to have been conducted according to 
OECD Guideline 408 and following Good Laboratory Practice (GLP) conditions. Groups of ten male 
and ten female Swiss albino mice were administered CMC by gavage daily at the doses of 100 mg/kg, 
300 mg/kg and 1000 mg/kg bw for 90 days. The concurrent control group received the vehicle 
(distilled water) only at 10 ml/kg bw. Additionally, satellite groups of ten mice per sex receiving the 
vehicle at 10 ml/kg and the test article at 1 000 mg/kg levels were further observed for a period of 28 
days following 90 day exposure, for assessment of reversibility, persistence or delayed occurrence of 
toxicity. The applicant notes that the results of the 90-day study indicate that CMC had no adverse 
effects on general health, growth, behavioural, neurological, haematological, clinical chemistry and 
urinalysis parameters, organ weights and gross findings and histo-pathological alterations in mice 
treated with up to 1000 mg/kg body weight, the highest dose tested. Based on the findings of the 90-
day study, the applicant considers that the no observed adverse effect level (NOAEL) of CMC in 
mice, following oral administration, was 1000 mg/kg body weight, the highest dose tested.  
However, the Panel considers that the study and the study report suffer from many shortcomings. 
EFSA has requested the applicant to address these shortcomings. Some of the issues could 
satisfactorily be clarified by the applicant. However, several limitations remained after consultation of 
the applicant: Prior to administration by gavage, doses of CMC in distilled water were prepared fresh 
each day but actual levels of the test substance in the suspensions were not confirmed analytically; 
Actual recording of absence of clinical abnormalities did not take place, and clinical observations 
which were seen in both controls and dose groups were not recorded either; As far as concerns 
histopathology, the applicant indicates that “all tissues mentioned in OECD 408 were screened for 
abnormalities, if any”, and that “the tissues showing histological findings were recorded”, but it is not 
clear which tissues were examined microscopically; Moreover, the applicant indicates that “normal 
histological appearances [were] not recorded”; Statistical analyses seem only to have been done on 
body weight and clinical chemistry, and the lack of any reported statistically significant difference in 
any parameter is rather unusual for a 90-day study. The Panel also notes the unusually straight line of 
increases in body weight, and the fact that the strain of mice used was only specified as “Swiss albino 
mice”. 
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Apart from information on the safety of the hydrolysis moieties and in the absence of sufficient data 
with respect to kinetics of hydrolysis, adequate safety information on the parent compound CMC 
remains relevant. The Panel considers that the new 90-day study and its study report have many 
shortcomings and cannot serve as a reliable source of information supporting the absence of adverse 
effects of CMC.  
The Panel concludes that the safety of 'Cetyl Myristoleate Complex' has not been established. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 9 July 2010, EFSA adopted a Scientific Opinion on the safety of „Cetyl Myristoleate Complex‟ as 
a food ingredient (EFSA, 2010).  
The conclusion of the EFSA opinion was that, based on the existing data, the safety of Cetyl 
Myristoleate Complex has not been established. The applicant has now provided additional 
information, in particular a study report “Repeated Dose 90 day Oral Toxicity Study with 28 Day 
Recovery Period or Celylated Fatty Acid Esters Powder 50 % in Mice”. The applicant is asking to 
assess the safety of Cetyl Myristoleate Complex in food supplements. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
In view of the above, the Commission requests EFSA to review and update its opinion in the light of 
the additional information. 
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ASSESSMENT 
1. INTRODUCTION 
In 2009, the European Commission asked EFSA to carry out an assessment of the safety of „Cetyl 
Myristoleate Complex (CMC)‟ with an intended daily intake of 3.3 g per person per day in the context 
of Regulation (EC) No 258/97. In 2010, the Panel concluded that based on the available data, the 
safety of CMC has not been established (EFSA Panel on Dietetic Products, Nutrition and Allergies 
(NDA), 2010). 
This conclusion was based on the considerations that (i) a provided rat study on the absorption and 
distribution of 
14
C-labelled cetylated fatty acids (CFA) had limitations in the design and the test 
substance used with respect to the proposed novel food ingredient, that (ii) no information was 
provided on the extent of intestinal hydrolysis of the CFA after oral intake, that (iii) limited 
information was provided on the distribution of absorbed unhydrolysed CFA and that (iv) no 
information was provided on the metabolism and excretion of such intact CFA. In the absence of 
appropriate data on absorption, distribution, metabolism and excretion (ADME), the provided 
toxicological data were considered insufficient. No subchronic oral toxicity study and no chronic 
toxicity study conducted with cetyl myristoleate or CMC had been provided in the original dossier.    
„Cetyl Myristoleate Complex‟ consists of 50 % cetylated fatty acids, 48 % corn starch and 2 % silicon 
dioxide. The applicant proposed a daily intake of 3.3 g CMC (1.65 g CFAs) which contains 
approximately 660 mg of both cetyl myristoleate and cetyl myristate, the two main compounds of 
CMC.  
2. ADDITIONAL INFORMATION PROVIDED 
In response to the considerations expressed by EFSA in 2010, the applicant provided a new subchronic 
oral 90-day toxicity study conducted with “Cetylated Fatty Acid Esters Powder 50 %” (Cetyl 
Myristoleate Complex, CMC) in mice (CMC Study Report, 2012).  
This 90-day study in mice was claimed by the applicant to have been conducted according to OECD 
Guideline 408 and following GLP conditions. However, the Panel notes that the study was not audited 
independently and that the test facility was not GLP certified. Groups of ten male and ten female 
Swiss albino mice were administered CMC by gavage daily at the doses of 100 mg/kg, 300 mg/kg and 
1000 mg/kg body weight for 90 days. The concurrent control group received the vehicle (distilled 
water) only at 10 ml/kg. Additionally, satellite groups of ten mice per sex receiving the vehicle at 
10 ml/kg and the test article at 1000 mg/kg levels were further observed for a period of 28 days 
following 90 day exposure, for assessment of reversibility, persistence or delayed occurrence of 
toxicity. 
Daily oral administration of CMC at dose levels of 100, 300 and 1 000 mg/kg bw to groups of ten 
Swiss albino mice per sex for 90 days was reported not to cause effects on: treatment related mortality, 
abnormal clinical signs, neurotoxicity, body weights, weekly food consumption, absolute and relative 
organ weights, haematological parameters, biochemical parameters, urinalysis parameters, gross 
findings and histo-pathological alterations in the tissues. The applicant notes that the results of the 90-
day study indicate that CMC had no adverse effects in mice treated with up to 1 000 mg/kg bw, the 
highest dose tested. 
However, the Panel considers that the study and the study report suffer from many shortcomings. 
EFSA has requested the applicant to address these shortcomings. Some of the issues could 
satisfactorily be clarified by the applicant. However, several limitations remained after consultation of 
the applicant: Prior to administration by gavage, doses of CMC in distilled water were prepared fresh 
each day but actual levels of the test substance in the suspensions were not confirmed analytically; 
Actual recording of absence of clinical abnormalities did not take place, and clinical observations 
which were seen in both controls and dose groups were not recorded either; As far as concerns 
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histopathology, the applicant indicates that “all tissues mentioned in OECD 408 were screened for 
abnormalities, if any”, and that “the tissues showing histological findings were recorded”, but it is not 
clear which tissues were examined microscopically; Moreover, the applicant indicates that “normal 
histological appearances [were] not recorded”; Statistical analyses seem only to have been done on 
body weight and clinical chemistry, and the lack of any reported statistically significant difference in 
any parameter is rather unusual for a 90-day study. The Panel also notes the unusually straight line of 
increases in body weight, and the fact that the strain of mice used was only specified as “Swiss albino 
mice”. 
DISCUSSION 
In the previous Opinion on CMC it was concluded that the information available at that time was not 
sufficient to establish that the majority of the CFA is hydrolyzed with a kinetic comparable to shorter 
and longer fatty acid esters (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2010). 
It was also noted that short linear-chain aliphatic saturated primary esters with an alkyl chain length of 
up to C7 would undergo hydrolysis to yield their corresponding linear-chain aliphatic alcohols and 
linear carboxylic acids, and that any remaining non-hydrolysed esters are expected to be absorbed 
rapidly from the gastrointestinal tract as well, after which they are also expected to be hydrolysed 
(EFSA, 2008). As concerns long-chain fatty alcohols esterified to long-chain fatty acids, EFSA noted 
that there is some information that long chain fatty acid esters are hydrolysed but at a slow rate 
(EFSA, 2008; EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2010). 
Cetylated fatty acids remain intact in the gastro-intestinal tract or are partically or completely 
hydrolysed into cetyl alcohol (1-hexadecanol) and the fatty acids to which cetyl alcohol is esterified. 
In the event that all of the CFA would be hydrolysed, the potential adverse effects of CMC would be 
related to the two hydrolysis moieties: fatty acids and cetyl alcohol. The Panel considers that the fatty 
acid moieties of CFA do not raise safety concerns as fatty acids are normal constituents of the diet and 
human body. Hence the potential adverse effects of the hydrolysis products of CFA relate to the cetyl 
alcohol which accounts for grossly half of the proposed CFA intake corresponding to approximately 
12 mg/kg bw. Human health risk assessment of long chain alcohols, including cetyl alcohol (OECD, 
2006; Veenstra et al., 2009). It was concluded that the NOAEL in repeated dose toxicity studies (28 
day, 13-week and reproduction toxicity tests) were all in a similar range, with the lowest value at 
750 mg/kg bw based on cetyl alcohol as the representative linear aliphatic alcohol (Veenstra et al., 
2009).   
Apart from information on the safety of the hydrolysis moieties, and in the absence of sufficient data 
with respect to kinetics of hydrolysis, adequate safety information on the parent compound CMC 
remains relevant. The Panel considers that the new 90-day study and its study report have many 
shortcomings and cannot serve as a reliable source of information supporting the absence of adverse 
effects of CMC.  
CONCLUSION 
The Panel concludes that the safety of 'Cetyl Myristoleate Complex' has not been established. 
DOCUMENTATION PROVIDED TO EFSA 
1. Dossier consisting of: a) Study Report “Repeated Dose 90 day Oral Toxicity Study with 28 Day 
Recovery Period of Cetylated Fatty Acid Esters Powder 50% in Mice”, Sponsor: EHP Products, P 
OBox. 2027 Mt. Pleasant, SC 29465, Testing facility TOXINDIA, Plot No. 52, Nilesh Park, 
Mahesh Soc., Bibwewadi, Pune - 411037, (INDIA).Report: R1140402/S0M·90/11, dated 
10 January, 2012, 122 pp and b) File called “2012-03-09 add info introduction.doc”, author: Dal 
Maso, dated 12 March, 2012. Additional information from the applicant was submitted on 
15 January and 18 March 2013. 
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2. Letter from the European Commission to the European Food Safety Authority with the request to 
review the opinion on the safety of „Cetyl myristoleate complex‟ Ref. Ares(2012)700835 - 
12/06/2012 received on 12 June 2012. 
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ABBREVIATIONS 
ADME Absorption, distribution, metabolism and excretion 
Bw Body weight 
CFA(s) Cetylated fatty acid(s) 
CMC Cetyl Myristoleate Complex 
GLP Good Laboratory Practice 
NF(I) Novel food (ingredient)  
NOAEL No observed adverse effect level 
OECD Organisation for Economic Co-operation and Development  
